Business
GCAN Receives Purchase Order for 125,000 Units of its Oral Cannabis Patch from Symtomax
GCAN Receives Purchase Order for 125,000 Units of its Oral Cannabis Patch from Symtomax.
About this update from Greater Cannabis Co Inc.
[{"type":"text","content":"\n BALTIMORE, MD, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Greater Cannabis Company (OTCQB: GCAN), an innovator in the development and commercialization of cannabinoid delivery systems and cannabinoids products is proud to announce that it has received a purchase order for 125,000 units of its eluting transmucosal patch. GCAN’s oral patch has been shown in clinical studies to be a safe and effective way to deliver lower doses of pharmaceutical actives, while achieving high levels of bioavailability. The purchase order came via Greater Cannabis’ European distribution partner Symtomax. The first Oral Tabs contain 21mg of full spectrum CBD in each sachet and will be available in 5 and 30 pack boxes in berry mint flavor with additional packet sizes, formulations and flavors planned for later on in the year. Symtomax has sourced numerous retail outlets and pharmacies for the distribution of the product, and is in further discussions with major distributors in a number of European countries. In addition to commercializing its own line of cannabis infused products, Symtomax has begun implementation of its low cost, high quality cannabis production facility in Portugal, which has approval for 95 hectares of cultivation, and when fully operational will be able to produce 700 Tons per year, making it one of the largest European cultivators. Paul Segal, Chairman of Symtomax, had this to say, “We are excited to finally begin the introduction of our first product into what will soon be a robust line of science-based cannabis products. Our Oral Tabs fill an unmet need from the lens of the cannabis consumer by providing a method of cannabis consumption that can be used anywhere, tastes great, and that works fast and has no side effects.” Paul further stated, “We are already seeing demand from our retail and distribution partners, and expect to see that increase as we ramp up marketing, and consumers begin trying the product.” Part of the Symtomax agreement calls for a revenue share of products sold through Symtomax distribution channels. In addition to the commercialization of the Oral Tabs through retail locations throughout Europe Symtomax is also advancing discussions to explore pharmaceutical applications of the GCANRx technology. Aitan Zacharin, CEO of Greater Cannabis, said in a statement to shareholders, ...